Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INDEPENDENT V. CHAIN AVERAGE Rx PRICE DIFFERENTIAL

Executive Summary

INDEPENDENT V. CHAIN AVERAGE Rx PRICE DIFFERENTIAL declined to 3› in 1985, according to the newly released 1986 edition of the NACDS-Lilly Digest of chain drug store operations. The 1984 retail price differential was 10›. The average prescription charge in chain pharmacies was $13.01 in 1985, up $1.11 (9.3%) from the average price of $11.90 in 1984, the Digest reports. In contrast, the 1986 Lilly Digest of independent drug store operations reported that the average prescription price in community pharmacies rose in 1985 to $13.04, up $1.04 (8.7%) from the previous year's average of $12 ("The Pink Sheet" Oct. 13, p. 10). Published by Lilly in cooperation with the National Association of Chain Drug Stores, the report presents summary data from 1985 operations of 746 chain pharmacies pharmacies across the country. The number of Rxs dispensed by the typical chain pharmacy totaled almost 50,000 during 1985, a 9.7% increase from the 1984 figure of 45,495. The ratio of new to renewed Rxs dispensed remained essentially the same as recorded last year. The average total sales of a chain store averaged just over $2.27 mil. and represented an 0.6% decline from the 1984 revenue, according to 1985 operating data. The figure represents the first time that the average NACDS-Lilly Digest pharmacy reported a decline in total sales when compared with the previous year's figure. Miscellaneous operating expenses showed a substantial increase both in dollars and as a percent of total sales when compared with the previous year's figure -- moving from 10.3% of sales in 1984 to 11.1% in 1985. The Digest reports that "data indicate that the increase in overall miscellaneous operating expenses resulted from higher expenditures for insurance, license, and taxes, as well as advertising and headquarters fee." Headquarters fee accounted for a major portion of the increase -- rising from 2.8% of sales in 1984 to 3.8% during 1985. Total wage package (manager's salary plus employees' wages), however, fell to 10.1% of sales -- down from 10.4% in 1984, representing the lowest total wage-package figure ever recorded by NACDS-Lilly Digest participants. The average floor area per unit increased almost 12% or 1,068 feet to 10,200 square feet in 1985. The report notes that the nonprescription area was responsible for virtually the entire increase. The 1986 edition will be the final issue of the chain digest. In a foreword, NACDS President Robert Bolger explains that the report "is no longer needed." The association has "recognized that chain store performance is better measured against corporate internal standards rather than digest averages, which are based on many, diverse stores."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS010997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel